OptiBiotix Health PLC (LON:OPTI) said it has appointed Dr Sofia Kolyda as director of research & development with immediate effect.
The AIM-listed life sciences group, which develops compounds to tackle obesity, high cholesterol, and diabetes, said Kolyda’s expertise had been important in the development of its technology through laboratory studies, human studies and manufacturing scale up, which had allowed it to create a pipeline of products.
WATCH: OptiBiotix Health sees revenues build as agreements turn into commercial deals
The firm added that Kolyda’s scientific leadership had been key to the company winning best scientific publication at the Probiota industry event in 2017 and 2018.
OptiBiotix also said that under Kolyda’s tenure it had secured agreements with several global corporates, including Tata for microbiome modulation and two agreements for its SweetBiotix range of sweeteners, the first with one of the world's largest suppliers of nutritional products and the second with one of the world's largest providers of dairy products.
Given the high levels of interest in SweetBiotix, Kolyda would take responsibility for leading development programmes with current and future corporate partners.